TC Medical(SH:600763)2025-10-27 09:10Financial Performance - The company's operating revenue for Q3 2025 was CNY 841,767,292.73, representing a year-on-year increase of 2.34% compared to CNY 822,546,825.43 in the same period last year[6]. - The net profit attributable to shareholders for Q3 2025 was CNY 192,342,867.51, reflecting a 2.15% increase from CNY 188,458,962.91 in the previous year[6]. - The total profit for Q3 2025 was CNY 264,319,791.56, which is a 1.36% increase from CNY 260,921,070.30 in the previous year[6]. - Total operating revenue for the first three quarters of 2025 reached ¥2,290,207,568.44, an increase of 2.54% compared to ¥2,233,126,548.77 in the same period of 2024[20]. - Net profit attributable to shareholders of the parent company was ¥513,500,420.93, an increase of 3.46% from ¥497,775,111.17 in the same period last year[21]. - The company reported a total comprehensive income of ¥621,042,989.70, compared to ¥593,597,480.85 in the previous year, marking a rise of 4.63%[21]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 6,227,937,341.37, showing a 0.82% increase from the previous year's end[6]. - Total assets as of September 30, 2025, are ¥6,278,898,835.13, compared to ¥6,227,937,341.37 at the end of 2024[15]. - Total liabilities decreased to ¥1,576,111,460.17 from ¥1,868,876,168.38, a reduction of approximately 15.59%[20]. - Total equity increased to ¥4,702,787,374.96 from ¥4,359,061,172.99, reflecting a growth of about 7.87%[20]. Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 681,619,443.27, an increase of 5.34% compared to CNY 646,768,804.91 in the previous year[6]. - Cash inflow from operating activities for the first three quarters of 2025 was approximately $2.31 billion, an increase from $2.25 billion in the same period of 2024, representing a growth of about 2.0%[23]. - Net cash flow from operating activities for the first three quarters of 2025 was $681.62 million, compared to $647.09 million in 2024, reflecting an increase of approximately 5.4%[23]. - The ending cash and cash equivalents balance for the first three quarters of 2025 was $576.72 million, down from $597.24 million in 2024, reflecting a decrease of about 3.5%[24]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 97,987[11]. - The largest shareholder, Hangzhou Baoqun Industrial Group Co., Ltd., holds 151,589,199 shares, representing 33.89% of total shares[12]. - The company has no pledged shares among the top shareholders, with the largest shareholder having 98,476,672 shares pledged[11]. - The company has no significant changes in the shareholder structure due to securities lending activities[12]. Investments and Acquisitions - The company completed the acquisition of 100% equity in Hangzhou Haiyin Kechuang Co., Ltd. in October 2024, and 100% equity in Shanghai Cunjing Hospital Dental Clinic Co., Ltd. in August 2025, leading to retrospective adjustments in financial reporting[5]. - Total cash outflow from investing activities in the first three quarters of 2025 was $324.33 million, down from $401.02 million in 2024, indicating a decrease of about 19.1%[24]. - Net cash flow from investing activities for the first three quarters of 2025 was -$311.24 million, compared to -$259.21 million in 2024, showing a worsening of approximately 20.1%[24]. Earnings Per Share - The basic earnings per share for Q3 2025 was CNY 0.43, up 2.38% from CNY 0.42 in the same period last year[6]. - Basic and diluted earnings per share for the period were both ¥1.15, up from ¥1.11 in the previous year[22].